Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

Recruiting now · Not applicable

Conditions studied: Obsessive-Compulsive Disorder

In brief

The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Key facts

Study ID

NCT02431845

Run by

Severance Hospital

People needed

200

Starts

2013-01-01

Expected to finish

2030-12-31

Last updated by the study team

2024-12-27

Who can join

Age: 19 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age 19\~ 70
• OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV)
• drug naive or drug free for more than 3 months

You may not qualify if…

• any neurological disorder
• comorbid psychotic disorders
• alcohol or other substance dependence within past 6 months
• any evidences for brain diseases

Where it is running

• Yonsei Univ. Health System Severance Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.